Cognitive decline and physical frailty are often siloed in clinical research and longevity interventions. This review fundamentally challenges that separation by demonstrating that bodily aging and brain aging share systemic biological drivers. Rather than treating dementia as an isolated neurological event, the data heavily indicates that the physical breakdown of the body—frailty—modulates the expression of cognitive disease.
Through a comprehensive scoping review of 3,090 screened articles, narrowed to 33 high-quality human studies, researchers identified 76 unique blood biomarkers. Of these, 38 were significantly associated with frailty, cognitive decline, or both. Crucially, five specific biomarkers independently overlap both conditions: A disintegrin and metalloproteinase 10 (ADAM10), fibrinogen, interleukin-6 (IL-6), neurofilament light chain (NfL), and vitamin D.
The identification of these shared biomarkers maps directly onto the established hallmarks of aging. Elevated IL-6 and fibrinogen clearly point to chronic “inflammaging” and immune dysregulation as a core driver. Reductions in vitamin D highlight deregulated nutrient sensing and metabolic dysfunction. Meanwhile, altered levels of ADAM10 and elevated NfL flag the breakdown of proteostasis and structural cellular integrity.
For the longevity and biotech communities, the implications are highly actionable. Classic Alzheimer’s markers, such as beta-amyloid and phosphorylated tau, are frequently measured without accounting for the patient’s physical frailty—a major oversight that obscures true biological age and resilience. The presence of overlapping peripheral markers suggests that interventions targeting systemic physical robustness may simultaneously preserve cognitive function. By targeting the shared mechanisms of inflammation, proteostasis, and nutrient sensing, the scientific community can move beyond single-disease management toward a unified strategy for healthspan extension.
Source:
-
Open Access Paper: Blood biomarkers of frailty and cognition: A scoping review
-
Institution: Dalhousie University, Halifax, Nova Scotia, Canada.
-
Journal: Neurobiology of Aging, May 2026 Issue
-
Impact Evaluation: The impact score of this journal is 3.5, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.
Mechanistic Deep Dive:
-
Chronic Inflammation (NF-kB/Cytokine Cascades): IL-6 and fibrinogen are consistently elevated in both physical frailty and cognitive decline. IL-6 acts as a peripheral inflammatory marker capable of crossing and disrupting the blood-brain barrier, driving neuroinflammation, and shrinking hippocampal volume. Elevated fibrinogen drives pro-inflammatory leukocyte migration and correlates with synaptic loss and neurovascular dysfunction. [Confidence: High]
-
Disrupted Proteostasis (APP Processing & Axonal Integrity): * ADAM10: Reduced active platelet ADAM10 limits its role as an alpha-secretase, shifting amyloid precursor protein (APP) processing away from neuroprotective pathways and toward toxic beta-amyloid accumulation.
-
NfL: Elevated neurofilament light chain signals active axonal injury and breakdown of the blood-brain barrier. Crucially, its link to frailty suggests neuromuscular junction failure and peripheral nerve degradation. [Confidence: High]
-
Deregulated Nutrient Sensing & Oxidative Stress: Reduced Vitamin D impairs calcium homeostasis (critical for neuronal action potentials and bone density) and removes a key systemic buffer against oxidative stress and leukocyte telomere attrition. [Confidence: Medium]
Novelty: This paper systematically forces the intersection of physical and cognitive aging metrics. While we knew frailty and dementia often co-occurred, we did not have a mapped, biomarker-level consensus of their shared systemic drivers. Furthermore, it exposes a massive blind spot in current neurology: beta-amyloid and tau levels are heavily confounded by the patient’s physical frailty status, yet frailty is rarely controlled for in cognitive biomarker research.
Critical Limitations:
-
Translational Uncertainty (Correlation vs. Causation): The data relies overwhelmingly on cross-sectional studies (29 of 33). It is unknown whether these biomarkers are upstream drivers of aging or downstream exhaust fumes of cellular damage. [Confidence: Low on causality]
-
Methodological Weaknesses: Massive dataset heterogeneity. Over 56% of the 104 evaluated relationships were single-study observations, meaning replicability is severely lacking. Furthermore, crude cognitive screens like the Mini-Mental State Examination (MMSE) were used in 26 studies, heavily under-detecting mild cognitive impairment.
-
Missing Data: The field is bottlenecked by targeted biomarker panels. There is a total absence of exploratory multi-omics (transcriptomics, epigenomics) to identify novel pathways. Additionally, despite aging biology being heavily sexually dimorphic, sex-stratified analysis was virtually ignored (only 5 studies assessed sex differences, and none assessed gender).